Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Neoleukin Therapeutics Inc.
Headquarters: Seattle, WA, United States of America
Website: N/A
Year Founded: 2004
Status: Reverse-merged
BioCentury | Oct 10, 2024
Discovery & Translation
Baker and DeepMind Nobel: Two sides of a computational protein coin
Protein design updates its engine: The field’s shift from physical models to deep learning
BioCentury | Dec 20, 2023
Data Byte
2023’s biotech reverse mergers
Half of the U.S.-listed biotechs that announced reverse mergers this year had been public for four years or less
BioCentury | Jul 28, 2023
Deals
Biotech reverse mergers growing amid improving market conditions
Are 2023’s reverse mergers another sign of an improving biotech environment?
BioCentury | Jul 18, 2023
Finance
July 18 Quick Takes: Pfizer, Flagship to launch up to 10 single-asset programs
Plus: J&J joins the IRA litigation club and updates from Novartis, Neurogene and Renibus
BioCentury | Mar 10, 2023
Management Tracks
Drachman leaving Neoleukin amid restructuring
Plus: Aspesi to lead HR at Editas and updates from Homology, GlycoMimetics and Ajax
BioCentury | Nov 5, 2022
Discovery & Translation
A gene therapy to drive hyperexcitable neurons back to baseline; plus a conditionally active IL-2 and more
BioCentury’s roundup of translational news
BioCentury | Aug 13, 2022
Product Development
Protein design updates its engine
The field is shifting from physical models to deep learning
BioCentury | Mar 18, 2022
Product Development
The IL-2 cancer pipeline remains deep, diverse
There’s still hope for ‘not-alpha’ IL-2 therapies after Nektar’s Ph III failure, with a pipeline full of diverse modalities and MOAs
BioCentury | Mar 10, 2022
Management Tracks
Ho becomes CFO at Third Harmonic
Plus updates from Orna, Prelude, Joseph Damond and more
BioCentury | Nov 16, 2021
Product Development
With trial starts and a takeout, γδ therapies start coming of age
Company data at SITC and ASH for antibodies and cell therapies directing γδ T cells to kill cancers
Items per page:
1 - 10 of 26